Defining the standard of care: Randomized controlled trials for the treatment of hepatitis C in the HIV-infected person†
Version of Record online: 25 MAR 2004
Copyright © 2004 American Association for the study of Liver Diseases
Volume 39, Issue 4, pages 906–908, April 2004
How to Cite
Sulkowski, M. S. (2004), Defining the standard of care: Randomized controlled trials for the treatment of hepatitis C in the HIV-infected person. Hepatology, 39: 906–908. doi: 10.1002/hep.20191
See Article on Page 989
- Issue online: 25 MAR 2004
- Version of Record online: 25 MAR 2004
- 5Centers for Disease Control and Prevention. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. USPHS/IDSA Prevention of Opportunistic Infections Working Group. US Public Health Services/Infectious Diseases Society of America. MMWR 1999; 48(R-10): 1–82.
- 11A randomized, controlled trial of pegylated interferon alpha-2s with ribavirin versus interferon alpha-2a with ribavirin for the treatment of chronic HCV in HIV co-infection: ACTG 5071 [abstract LB15]. Ninth Conference on Retrovirology and Opportunistic Infections; February 24–28, 2002; Seattle, WA., , , , , , et al.
- 12RIBAVIC trial (ANRS HC02): a controlled randomized trial of pegylated-interferon alfa-2b plus ribavirin versus interferon alfa2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients: preliminary results. In: XIVth World AIDS Conference. Barcelona, Spain, 7–12 July 2002 [abstract LbOr16]., , .